Ask the Experts Interview Series

/

Casper Breum

Before founding Sound Bioventures, Mr. Breum was a Senior Partner at Lundbeckfonden Ventures, where he worked for 12 years, and led investments and served as a member of the board of directors in companies including Sanifit (sold to Vifor Pharma), Aura Biosciences (Nasdaq: AURA), Spero Therapeutics (Nasdaq: SPRO), Nexstim (Nasdaq First North: NXTM), Biomup (Euronext: BUP).

Prior to that, he was CEO of the venture-backed diagnostics company, ilochip A/S (technology sold to DELTA, now FORCE Technology). Before that, Mr Breum worked in the pharmaceutical industry for 15 years in a range of different positions in R&D, Project Management, Sourcing, Quality Assurance, and Business Development & Strategy, for Lundbeck, Novo Nordisk and Niels Clauson-Kaas. While working at Lundbeck, Mr. Breum was part of spinning Veloxis (sold to Asahi Kasei) out of Lundbeck, and served on the board of the Lundbeck Foundation.

Mr. Breum holds a MSc in organic chemistry and an Executive MBA, both from the Technical University of Denmark

 

Published: September 12, 2024 6:50 am UTC+0

Ask the Experts Interview Series

with Casper Breum

Tell us about your background.

I am an organic chemist who has worked in many different fields within pharma and biotech. I have worked at Novo Nordisk, H. Lundbeck and at a Danish CRO working in different areas and roles such as QA, R&D Chemistry, Project Management, Sourcing and Corporate Business Development and Strategy. Before I started my venture trajectory, I was CEO of a venture-backed diagnostic company. My time in venture capital started in 2009 at Lundbeckfonden Ventures when the Lundbeck Foundation decided to establish a VC entity.  

You’re currently leading the Sound Bioventures team as Managing Partner. What is the fund’s focus and how was it set up?

Sound Bioventures focuses on the development of therapeutic drugs only, and only drugs that are already in clinical trials or very close to the first clinical trials in humans. We have no specific therapeutic area focus. In fact, I would say we are therapeutic area agnostic, but very strong believers in good teams and drug development projects that will really move the needle for the patients and healthcare providers it is supposed to help.

Who/what was the impetus for founding this fund?

While working for the Lundbeck Foundation, my colleague and now partner at Sound Bioventures, Johan Kördel, and I often talked about starting an independent VC shop. Although we had a lot of freedom at the Lundbeck Foundation, we wanted the experience of being fully responsible for our own fund management company. 

Congratulations on the various successes to-date. Which project was the most memorable?

Sound was established towards the end of 2021, so we are still very young as a biotech VC fund. In fact, we still have about 3 investments to do in the first fund. We have no exits yet, and no failures. Proof of our success as investors in the Sound setting is still in the pudding. Having said that, we see it as an enormous success that we managed to raise the fund and to build the organization to where it is now. We have been able to recruit a team of really good investment professionals and a wonderful office manager who manages a large part of all the practical things that are needed when you run a company, makes sure we are in the right place at the right time and takes good care of us in general.

The team invests on both sides of the Atlantic. Is there a stark difference when it comes to market dynamics and culture?

Deals tend to be larger and more expensive in the US. There is a larger number of large funds in the US and more capital is being invested at earlier stages. This makes it a bit tricky for smaller funds to invest enough to reach meaningful ownership in US companies and therefore it is harder to find opportunities with the right fit. When things change in the US, it often trickles into Europe.

We have some quite large funds here already and we are beginning to see companies that want to raise large amounts of money. In some ways, this is good because some European companies are underfunded compared to the potential of the drug. When it comes to culture there are certainly some differences, but overall, it is not more different than the difference between the culture in northern Europe and southern Europe. 

how IS the current team run?

At Sound, we work very much like a matrix organisation. For every deal, we appoint a two-member team with a Partner and a team member. This team runs the due diligence, and if the case goes all the way, the partner joins the board of the company, and often the other member of the two-person team joins as a board observer. We focus very much on the development of the team members and try to give them more responsibility sooner rather than later. However, that doesn’t necessarily mean that promotion happens quickly. The most important part of our business cannot be taught, and that is experience. To be a good venture investor you need to have that experience.

Everyone at Sound Bioventures has had experience in industry before going into VC. How has that shaped you as a team?

We take pride in that fact, and we think it gives a better understanding of what we are dealing with in the companies. It gives a better understanding of the investment cases and it becomes easier to judge if different events are critical or minor hick-ups that can be fixed.

We’re going into the autumn of 2024. What is the current sentiment in the investment industry?

I think it depends on who you ask and in what part of the industry they are. We see a steady flow of good cases, and valuations are more or less as usual. The tricky part is probably raising capital for emerging funds and in some cases even for established funds. So far, we have done exactly what we said we would do and there are several of our portfolio companies that look promising in the nearer term. Maybe that helps. Time will tell.

What’s your take on leadership? 

That is a big question. I believe in freedom and trust. We hire smart people with solid educations, so they can do a lot, and we let them to a large extent. But with that freedom comes a lot of responsibility. Not only responsibility for doing a good job but also for knowing when to ask and for being a stellar representative of Sound. We want to be known for doing a solid job, and for being someone you can trust as a partner. This is some of what we expect in return for that freedom and trust.

What is one interesting fact about yourself that few people know of (a hobby, etc.)? 

Don’t tell our ESG people, but I like driving high-powered combustion engine cars really fast on racetracks.

Do you have any final remarks/advice to share?

Respect all people you meet, do the best you can, and be a decent person. That will solve many problems in the world in general.

Insights

Related articles

Margrit Schwarz

Who inspired you to get into the life sciences? My interest for life science was nurtured by my father, who was both a chemist and a photographer; he took me along on hikes and then to the lab where I spent hours staring through a microscope, examining the things I had just picked up on the trail. It instilled in me a deep fascination for all things ‘Nature’, from patterns of life that repeat regardless of scale, to endless curiosity for – simply put – why things are the way they are!

Read More

Stephan Christgau

You have an extensive background in both academia and the biotech industry, with over 60 peer-reviewed papers and multiple patents. How has your experience as a researcher shaped your approach as a life sciences investor and entrepreneur?

I think it gives a different perspective as an investor, when you have actually had operational experience. Having started companies and worked with f.ex. patent strategy, development plans and CRO selection and monitoring is not only something I hear about in the board room, but something I have actually done myself.

That said, one should of course also be humble and recognize that one’s own experience is only directly relevant in few cases, and of course we engage experts and other stakeholders in all cases, but it is nevertheless a different perspective one gets from having started and run companies.

The scientific background, and ability to grasp and challenge scientific backgrounds of projects and companies, is essential for an investor in the life science space, and indeed I believe most of my peers in other venture funds have scientific and/or clinical backgrounds.

Read More

John Boghossian

Can you share the inspiration and vision behind founding Kadence Bio?
The inspiration for Kadence Bio stemmed from our founders’ early investigations into potential acute treatments for mood disorders, where they explored different classes of alkaloid small molecules. We discovered a compound scaffold with a distinctive pharmacokinetic profile that also exhibited an unexpected effect of delayed ejaculation. This – rather unexpected! – The finding was corroborated by the elucidation of its potential mechanism of action. 
We then identified a significant unmet need, as no FDA-approved treatments exist for premature ejaculation, a condition that affects at least 1 in 20 men and their partners globally and hinders intimacy and well-being in these relationships. We quickly decided to found Kadence Bio, with a vision of cultivating sexual and mental well-being by developing novel treatments for sexual health and mood disorder applications.

Read More

Sharon Cunningham

You are a chartered accountant turned biotech Founder-CEO. Can you share your journey with us? 
After graduating with a Bachelor of Science in Finance, I trained to become a Chartered Accountant with PwC. I later secured a role as a Management Accountant with pharmaceutical company, EirGen Pharma, progressed to Financial Controller and then Head of Finance. During my time there, I obtained my executive MBA. In 2018 I co-founded Shorla Oncology, a specialty pharmaceutical company developing and commercializing innovative oncology drugs addressing unmet needs. I come from an entrepreneurial family and I always knew I would run my own business eventually but I wanted to spend time in practice and industry and gain as much formal education as possible in order to maximise my knowledge and skills, build an industry network and ultimately enhance my credibility in order to ensure success. 

Read More